Kinetics of Inhibition of Monoamine Oxidase Using Curcumin and Ellagic Acid.
BACKGROUND
Curcumin and ellagic are the natural polyphenols having a wide range of pharmacological actions. They have been reported to have their use in various neurological disorders.


OBJECTIVE
This study was aimed to evaluate the effect of curcumin and ellagic acid on the activity of monoamine oxidase (MAO), the enzyme responsible for metabolism of monoamine neurotransmitters which are pivotal for neuronal development and function.


METHODS
The in vitro effects of these selected polyphenols on MAO activities in mitochondria isolated from rat brains were examined. Brain mitochondria were assayed for MAO type-B (MAO-B) using benzylamine as substrates. Rat brain mitochondrial MAO preparation was used to study the kinetics of enzyme inhibition using double reciprocal Lineweaver-Burk plot.


RESULTS
MAO activity was inhibited by curcumin and ellagic acid; however, higher half maximal inhibitory concentrations of curcumin (500.46 nM) and ellagic acid (412.24 nM) were required compared to the known MAO-B inhibitor selegiline. It is observed that the curcumin and ellagic acid inhibit the MAO activity with both the competitive and noncompetitive type of inhibitions.


CONCLUSIONS
Curcumin and ellagic acid can be considered a possible source of MAO inhibitor used in the treatment of Parkinson's and other neurological disorders.


CONCLUSIONS
Monoamine oxidase (MAO) is involved in a variety of neurological disorders including Parkinson's disease (PD)Curcumin and ellagic acid inhibit the monoamine oxidase activityEllagic acid revealed more potent MAO type-B (MAO-B) inhibitory activity than curcuminKinetic studies of MAO inhibition using different concentrations of curcumin and ellagic acid were plotted as double reciprocal Lineweaver-Burk plotThe mode of inhibition of both compounds toward MAO-B is mixed (competitive and uncompetitive) type of inhibition with both the competitive and noncompetitive type of inhibitions. Abbreviations used: MAO: Monoamine oxidase, IC50: Higher half maximal inhibitory concentrations, PD: Parkinson's disease, LB: Lewy bodies, SNpc: Substantia nigra pars compacta, ROS: Reactive oxygen species, SG: Selegiline, DMC: demethoxycurcumin, BDMC: Bisdemethoxycurcumin.
Department of Pharmaceutical Sciences and Technology, Pharmacology Research Lab-II, Institute of Chemical Technology, (University under Section 3 of UGC Act-1956, Elite Status and Centre of Excellence, Government of Maharashtra, TEQIP Phase II Funded), Mumbai, Maharashtra, India.
Dharmendra Kumar
DK
Khatri
Department of Pharmaceutical Sciences and Technology, Pharmacology Research Lab-II, Institute of Chemical Technology, (University under Section 3 of UGC Act-1956, Elite Status and Centre of Excellence, Government of Maharashtra, TEQIP Phase II Funded), Mumbai, Maharashtra, India.
Archana Ramesh
AR
Juvekar
Curcumin; ellagic acid; enzyme; inhibition; kinetics; monoamine oxidase-B